Taysha Gene Therapies, Inc.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.8M
- Net income
- -$109.0M
- Total assets
- $343.3M
- Market cap
- $1.6B
- Operating margin
- -1130.6%
- Net margin
- -1115.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.8M
- Operating expenses
- $120.3M
- Operating income
- -$110.5M
- Income tax
- $0
- Net income
- -$109.0M
- EPS (basic)
- $-0.34
- EPS (diluted)
- $-0.34
Balance sheet
- Total assets
- $343.3M
- Current assets
- $324.6M
- Total liabilities
- $96.4M
- Current liabilities
- $26.6M
- Shareholders’ equity
- $246.9M
Cash flow
- Operating cash flow
- -$93.1M
- Investing cash flow
- -$604.0K
- Financing cash flow
- $274.6M
- Net cash flow
- $180.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-0.34
- Shares outstanding
- 291.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 24, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $109.0M in FY2025.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Taysha Gene Therapies, Inc..
Write a review
News about Taysha Gene Therapies, Inc.
News & sentiment via Polygon.io
